Phase 2

RRMM

Sponsor:

Multiple Myeloma Research Consortium

Code:

NCT06171685

Conditions

Relapse Multiple Myeloma

Refractory Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Teclistamab Monotherapy

Teclistamab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-27. This information was provided to ClinicalTrials.gov by Multiple Myeloma Research Consortium on 2026-06-05.